调节性T细胞在淋巴瘤中的预后作用：一项系统评价和荟萃分析。
Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis.
作者信息
Peng Fei, Qin You, Mu Shidai, Li Jingwen, Ai Lisha, Hu Yu
机构信息
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
出版信息
J Cancer Res Clin Oncol. 2020 Dec;146(12):3123-3135. doi: 10.1007/s00432-020-03398-1. Epub 2020 Sep 29.
PURPOSE
The regulatory T cells (Tregs) are a subpopulation of lymphocytes that suppress the immune responses. The prognostic value of Tregs in lymphoma patients remains controversial. Thus, we conducted this meta-analysis to clarify the role of Tregs in the prognosis of lymphoma patients.
METHODS
We searched PubMed, Embase, and Web of Science to obtain eligible studies that evaluated the prognostic factor of Tregs for lymphoma patients. Hazards ratios (HRs) with the matching 95% confidence intervals (95%CIs) were merged to estimate the prognostic value of Tregs.
RESULTS
We finally retrieved 23 eligible studies, including a total of 2269 patients. The overall pooled analysis on all types of lymphomas showed that Tregs had a significantly positive association with prolonged overall survival (OS) (HR = 0.633, 95% CI 0.528-0.758) and progression-free survival (PFS) (HR = 0.451, 95% CI 0.261-0.779). Subgroup analysis indicated that high Tregs were significantly correlated with longer OS in Hodgkin lymphoma, diffuse large B cell lymphoma, and natural killer/T cell lymphoma. However, there was no significant association of Tregs with T cell lymphoma and follicular lymphoma.
CONCLUSIONS
Increased Tregs indicates a better prognosis for patients with lymphoma. Tregs could be used as a valuable prognostic biomarker of lymphoma patients.
目的
调节性T细胞（Tregs）是一类抑制免疫反应的淋巴细胞亚群。Tregs在淋巴瘤患者中的预后价值仍存在争议。因此，我们进行了这项荟萃分析，以阐明Tregs在淋巴瘤患者预后中的作用。
方法
我们检索了PubMed、Embase和Web of Science，以获取评估Tregs对淋巴瘤患者预后因素的合格研究。合并具有匹配的95%置信区间（95%CIs）的风险比（HRs），以估计Tregs的预后价值。
结果
我们最终检索到23项合格研究，共纳入2269例患者。对所有类型淋巴瘤的总体汇总分析表明，Tregs与总生存期（OS）延长（HR = 0.633，95% CI 0.528 - 0.758）和无进展生存期（PFS）延长（HR = 0.451，95% CI 0.261 - 0.779）显著正相关。亚组分析表明，高Tregs与霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤和自然杀伤/T细胞淋巴瘤的较长OS显著相关。然而，Tregs与T细胞淋巴瘤和滤泡性淋巴瘤之间无显著关联。
结论
Tregs增加表明淋巴瘤患者预后较好。Tregs可作为淋巴瘤患者有价值的预后生物标志物。
Zotero 插件